Loading
institutionsInstitution
Cedars-Sinai Cancer
Los Angeles's largest non-profit hospital's cancer enterprise, known for bladder cancer biology, glioma immunotherapy and the Molecular Twin AI project.
Also called: Samuel Oschin Comprehensive Cancer Institute
Overview
Cedars-Sinai Cancer unites the Samuel Oschin Comprehensive Cancer Institute with Cedars-Sinai's regional network across Los Angeles. Director Dan Theodorescu's laboratory showed in 2023 that loss of the Y chromosome in bladder cancer drives immune evasion and sensitivity to checkpoint blockade; Keith Black's neurosurgery programme pioneered dendritic cell vaccines for glioma; and the Molecular Twin initiative combines multi-omics and AI to model individual patients, starting with pancreatic cancer. The centre has strong kidney, prostate, lung and women's cancer programmes and a phase 1 unit, and is pursuing NCI designation.
Location
Los Angeles, CA, US
Type
hospital
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#327 · 20 points (0 Newsweek + 0 NCI + 20 from 10 linked objects) · ranking
- Bladder cancer biology
- Neuro-oncology immunotherapy
- Molecular Twin (AI and multi-omics)
Armando E. Giuliano
Executive Vice Chair of Surgery, Cedars-Sinai Medical Center
Breast surgical oncologySentinel lymph node biopsyAxillary de-escalation
Brought sentinel node biopsy to breast cancer and led ACOSOG Z0011, which ended routine axillary dissection for many women.
Mark B. Faries
Co-Director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai
Melanoma surgerySentinel node biopsySurgical oncology
Surgeon who led MSLT-II, showing that removing all lymph nodes after a positive sentinel node does not improve melanoma survival.
Robert Figlin
Interim Director of Cedars-Sinai Cancer
Medical oncologyCancer centre leadershipTranslational research
Medical oncologist who has led Cedars-Sinai Cancer in Los Angeles as Interim Director since March 2025.
Stephen J. Freedland
Urologist, Cedars-Sinai Cancer
Prostate cancerBiochemical recurrenceDiet and lifestyle in prostate cancer
Los Angeles urologist who was lead author of EMBARK, the trial that established enzalutamide for men whose prostate cancer is returning fast after surgery or radiotherapy.
Similar pages
- Key paperIvermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)
Shares Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2), Ivermectin, Immune checkpoint inhibitors.
- TermRecommended phase 2 dose (RP2D)
Shares Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2), Ivermectin.
- IdeaBank three spatially separate tumour blocks from every resection
Shares Data silos, Renal cell carcinoma.
- IdeaLink bariatric and GLP-1 registries to cancer registries in every country that has both
Shares Data silos, Renal cell carcinoma, Pancreatic ductal adenocarcinoma.
- IdeaCapture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial
Shares Data silos, Renal cell carcinoma, Immune checkpoint inhibitors.
- CompanyAgenus
Shares Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2), Ivermectin.
- InstitutionUniversity of Florida Health Cancer Center
Shares Ivermectin, Glioma & glioblastoma.
- TechnologySystematic drug repurposing
Shares Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2), Ivermectin.
cancers
fronts
technologies
drugs
Phase 2Oral antiparasitic small molecule (macrocyclic lactone), studied in cancer as an add-on to checkpoint antibodies
Ivermectin · Stromectol